Rena Azar, MD
Urogynecology and Reconstructive Pelvic Surgery · South Pittsburg, TNNPI 1760537484
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (41.6%), other and food and beverage — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Duchesnay USA Incorporated at 43.7% of the total. Reporting peaked in 2019 at $11,123 and has fallen 94.2% since, to $649 in 2025.
Across 175 payments — averaging $130.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Duchesnay USA Incorporated$10K
- Medtronic$9K
- Boston Scientific$914
- Astellas Pharma US Inc$752
- AbbVie$261
- Pfizer$252
- plus $1K from 24 others
What the payments were for
- Speaking & faculty fees$9,50042%
- Travel & lodging$1,2686%
- Food & beverage$3,59816%
- Education$5943%
- Other$7,85734%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Duchesnay USA Incorporated | 17 | $9,972 |
| Medtronic | 27 | $9,432 |
| Boston Scientific | 10 | $914 |
| Astellas Pharma US Inc | 18 | $752 |
| AbbVie(2 entities) | 13 | $261 |
| Pfizer | 16 | $252 |
| Sumitomo Pharma America, Inc. | 9 | $187 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $158 |
| Myovant Sciences Inc. | 6 | $117 |
| Urovant Sciences Inc | 6 | $90 |
| Therapeuticsmd, Inc. | 5 | $84 |
| Eisai Inc. | 6 | $81 |
| Axonics, Inc. | 4 | $60 |
| AMAG Pharmaceuticals, Inc. | 4 | $49 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $48 |
| Coloplast | 2 | $46 |
| Biohaven Pharmaceuticals, Inc. | 3 | $45 |
| Laborie Medical Technologies Corp. | 2 | $32 |
| Exact Sciences | 2 | $29 |
| Exeltis, USA Inc. | 2 | $26 |
| Olympus America Inc. | 1 | $21 |
| TELA Bio, Inc. | 1 | $21 |
| Vertex | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Caldera Medical, Inc | 1 | $19 |
| Baxter Healthcare | 1 | $18 |
| Mayne Pharma Commercial LLC | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Avion Pharmaceuticals | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,817 in reported general payments places this provider in the 85th percentile of 24 urogynecology and reconstructive pelvic surgery providers in Tennessee.
See all urogynecology and reconstructive pelvic surgery providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 570 | $37,803 |
| GemtesaVibegron | 37 | $32,972 |
| OzempicSemaglutide | 22 | $29,279 |
| TrulicityDulaglutide | 27 | $25,987 |
| LinzessLinaclotide | 26 | $24,493 |
| PremarinEstrogens, Conjugated | 53 | $22,620 |
| MyrbetriqMirabegron | 12 | $10,392 |
| OsphenaOspemifene | 29 | $9,912 |
| VeozahFezolinetant | 12 | $7,236 |
| Clobetasol Propionate | 67 | $6,811 |
| Desmopressin Acetate | 120 | $5,864 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 192 | $5,732 |
| Lubiprostone | 14 | $5,166 |
| IntrarosaPrasterone (Dhea) | 12 | $4,150 |
| Methenamine Hippurate | 38 | $3,686 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $187 | $32,97237 claims |
| AbbVieLinzess | $261 | $24,49326 claims |
| PfizerPremarin | $252 | $22,62053 claims |
| Astellas Pharma US IncMyrbetriq, Veozah | $752 | $17,62824 claims |
| Duchesnay USA IncorporatedOsphena | $9,972 | $9,91229 claims |
| AMAG Pharmaceuticals, Inc.Intrarosa | $49 | $4,15012 claims |
| Therapeuticsmd, Inc.Imvexxy | $84 | $3,46415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 24 urogynecology and reconstructive pelvic surgery providers in Tennessee.
Other urogynecology and reconstructive pelvic surgery in South Pittsburg
- Tara AllenNashville$100K
- Barry JarnaginFranklin$57K
- C BowlingKnoxville$52K
- Marcy AbelNashville$22K
- Roland HuffakerJohnson City$17K
- Henry OkaforChattanooga$13K
- Carson KaeserChattanooga$10K
- Jeffrey McQuearyBristol$9K
- Val VogtGermantown$6K
- Jill DanfordNashville$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.